U.S. Oil and Gas Stock News

NasdaqGS:ACDC
NasdaqGS:ACDCEnergy Services

Assessing ProFrac Holding (ACDC) Valuation After Strong Recent Share Price Momentum

ProFrac Holding (ACDC) has drawn fresh attention after recent share price moves, with the stock down around 3% over the past week yet up sharply over the past 3 months and year to date. See our latest analysis for ProFrac Holding. That recent pullback comes after a strong run, with a 90 day share price return of 39.92% and a year to date share price return of 76.98%, even as the 3 year total shareholder return remains down 38.99%. If this kind of move has you thinking about where else...
NasdaqGS:ON
NasdaqGS:ONSemiconductor

Did Record Free Cash Flow, $6 Billion Buyback and New GaN Line Just Shift ON's (ON) Narrative?

Earlier this year, ON Semiconductor reported Q4 2025 non-GAAP EPS of US$0.64, generated record free cash flow, approved a US$6.00 billion buyback, and introduced vertical GaN power semiconductors targeting AI data centers and electric vehicles. The combination of strong cash generation, a very large repurchase plan, and new GaN products aimed at high-growth power markets has sharpened investor focus on how ON Semiconductor balances capital returns with long-term technology investment. We’ll...
NYSE:ADNT
NYSE:ADNTAuto Components

Is Adient’s Upgraded 2026 Outlook and China Momentum Altering The Investment Case For Adient (ADNT)?

At its recent J.P. Morgan Auto Group Investor Meeting, Adient raised its fiscal 2026 guidance after strong first-half execution, highlighting approximately US$1.10 billion in new annual business wins in China, 18% China sales growth in the first half of fiscal 2026, and continued market share gains in the Americas. Beyond higher guidance, the company emphasized how automation, AI-enabled smart manufacturing, and a new China joint venture are reshaping its operations and customer...
NYSE:XYL
NYSE:XYLMachinery

Is Xylem (XYL) Offering An Opportunity After This Year’s Share Price Weakness?

Wondering whether Xylem stock offers good value at today’s price, or if the recent moves are already pricing in its strengths. The share price closed at US$110.28, with a 7 day gain of 2.0%, but it is down 9.2% over the past 30 days and down 19.6% year to date. This may change how you think about both upside potential and risk. Over the past 1 year the stock is down 10.0%, while the 3 year return sits at 15.9% and the 5 year return is down 1.2%. This gives useful context for anyone looking...
NasdaqGS:MYRG
NasdaqGS:MYRGConstruction

Assessing MYR Group (MYRG) Valuation After Strong EPS Growth Free Cash Flow Gains And Share Buybacks

Why MYR Group (MYRG) Is On Investors’ Radar Now MYR Group (MYRG) is back in focus after reporting robust earnings per share growth, stronger free cash flow margins, and recent share repurchases that collectively point to a more efficient use of capital. See our latest analysis for MYR Group. The recent earnings strength sits alongside a sharp move in the stock, with a 30-day share price return of 31.72% and a 90-day share price return of 62.82%. The 1-year total shareholder return of 183.91%...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Why Regeneron (REGN) Is Down 8.5% After Melanoma Trial Miss and New Legal Scrutiny - And What's Next

Earlier in May 2026, Regeneron Pharmaceuticals reported that its Phase 3 trial of fianlimab plus cemiplimab in first-line metastatic melanoma did not reach statistical significance for progression-free survival versus pembrolizumab, prompting multiple law firm investigations into whether prior communications about the program misled investors. At the same time, Regeneron unveiled very strong early-phase data for Lynozyfic in relapsed systemic AL amyloidosis and advanced a new Helicon-based...
NYSE:FLO
NYSE:FLOFood

Does Flowers Foods' (FLO) Clean-Label Pivot and Dividend Cut Recast Its Long-Term Playbook?

Earlier this week, Flowers Foods reported first-quarter 2026 results showing net sales of US$1,571.58 million, modestly higher year on year, but with net income and earnings per share lower than the prior period, alongside updated full-year guidance, a reduced quarterly dividend of US$0.1250, and continued share repurchases. At the same time, the company relaunched its flagship Nature’s Own brand with simpler, Non-GMO recipes and a major multi-platform “Breaducator” marketing push, signaling...
NYSE:APG
NYSE:APGConstruction

APi Group (APG) Valuation Check After Recent Share Price Pullback And Recurring Revenue Growth Story

Recent performance snapshot APi Group (APG) has drawn fresh attention after a period in which the stock is up about 7% year to date, while showing declines over the past month and the past three months. See our latest analysis for APi Group. Short term, the stock has lost some momentum, with a 30 day share price return of down 14.34% and a 90 day share price return of down 5.62%. Its 1 year total shareholder return of 36.91% and 3 year total shareholder return of about 17x highlight how...
NasdaqGS:FFIV
NasdaqGS:FFIVCommunications

F5 (FFIV) Is Up 8.6% After Deepening Red Hat AI Security Integration Has The Bull Case Changed?

Earlier this month, Red Hat announced new milestones in its collaboration with F5, introducing F5 WAF for NGINX on NGINX Gateway Fabric and AI quickstarts for Red Hat OpenShift AI to enhance Kubernetes-native and AI-powered application security for enterprise customers. The move highlights how F5 is embedding security-as-code and validated AI chatbot architectures directly into cloud-native workflows, aiming to make advanced protection more accessible for organizations handling sensitive...
NYSE:LUXE
NYSE:LUXESpecialty Retail

Assessing LuxExperience B.V (LUXE) Valuation After Wider Losses And YNAP And THE OUTNET Reshaping

LuxExperience B.V (LUXE) drew fresh attention after reporting third quarter and nine month results that paired higher sales with a wider net loss, while also closing the sale of THE OUTNET and outlining a YNAP transformation plan. See our latest analysis for LuxExperience B.V. The latest quarter, with higher sales but a wider loss and fresh restructuring charges, has coincided with pressure on the stock, which is down 21.31% on a 1 month share price basis and 22.53% on a 1 year total...
NasdaqGM:RUM
NasdaqGM:RUMInteractive Media and Services

Rumble (RUM) Is Up 13.8% After Landing Exclusive Enhanced Games Streaming And Ad Partnership

In May 2026, Enhanced, an elite sports competition and consumer products company, announced a content and distribution partnership with Rumble to stream the inaugural Enhanced Games from Las Vegas and future events, while also leveraging Rumble’s Advertising Center to promote its Live Enhanced platform. This deal gives Rumble another live-sports style content vertical and a targeted advertising client that aims to improve customer acquisition efficiency using its platform. Next, we’ll...
NasdaqGS:VEON
NasdaqGS:VEONWireless Telecom

How VEON’s (VEON) Guidance Boost, Buyback and Refinancing Have Changed Its Investment Story

Earlier in May 2026, VEON Ltd. reported first-quarter 2026 results showing revenue of US$1,201 million versus US$1,026 million a year earlier, with net income steady at US$99 million and basic and diluted earnings per share from continuing operations unchanged at US$1.5. Alongside raising its 2026 revenue growth guidance, launching a US$100 million share buyback, and issuing US$1.4 billion of new bonds to refinance existing debt, VEON highlighted rapidly expanding digital revenues and...
NasdaqGS:ABCL
NasdaqGS:ABCLLife Sciences

AbCellera Biologics (ABCL) Valuation Check After ABCL635 Phase 1 Update And Improved Quarterly Results

AbCellera Biologics (ABCL) is back on investors’ radar after early Phase 1 data for its lead program ABCL635 and a fresh quarterly earnings report that shows higher revenue and a smaller net loss. See our latest analysis for AbCellera Biologics. The recent Phase 1 data for ABCL635 and the quarterly update appear to have coincided with a sharp acceleration in momentum, with the stock showing a 27.14% 7 day share price return, a 71.62% 90 day share price return, and a 163.96% 1 year total...
NasdaqGS:GENB
NasdaqGS:GENBBiotechs

Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer?

Earlier in May 2026, Nvidia invested US$10.40 million in Generate Biomedicines, an AI-driven biotech now advancing several drug candidates through clinical development, including a Phase 3 severe asthma program and oncology therapies with FDA Fast Track status. This combination of external validation from a major AI leader and visible clinical momentum underscores how AI-enabled drug discovery is moving from concept toward real-world testing. Next, we’ll examine how Nvidia’s investment and...
NYSE:BLSH
NYSE:BLSHCapital Markets

What Bullish (BLSH)'s Massive Equiniti Deal and ARK Buying Spree Means For Shareholders

Bullish recently reported first-quarter 2026 results showing US$20.01 million in sales and a net loss of US$581.71 million, while also announcing a US$4.20 billion acquisition of Equiniti and facing widening per-share losses versus a year earlier. Amid these developments and broader digital asset volatility, ARK Invest and other institutional investors have been actively building positions in Bullish, signaling renewed institutional focus on its role in tokenization and crypto-market...
NYSE:AMBQ
NYSE:AMBQSemiconductor

A Look At Ambiq Micro (AMBQ) Valuation After A Sharp Multi Month Share Price Surge

Ambiq Micro stock: quick context on recent performance Ambiq Micro (AMBQ) has been drawing attention after sharp recent gains, with the stock up 130% over the past month and up about 172% over the past 3 months. That move comes as investors weigh a US$1.75b market value against the company’s US$81.8m in revenue and a reported net loss of US$38.3m from its ultra low power semiconductor business. See our latest analysis for Ambiq Micro. At a share price of US$81.67, Ambiq Micro’s recent surge,...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

A Look At Intellia Therapeutics (NTLA) Valuation After Narrower First Quarter Loss

Intellia Therapeutics (NTLA) recently reported first quarter results showing a net loss of US$96.23 million and basic loss per share of US$0.81, compared with US$114.33 million and US$1.10 a year earlier. See our latest analysis for Intellia Therapeutics. Despite a recent 7 day share price return that declined 7.83% and a 30 day share price return that declined 7.56%, Intellia’s year to date share price return of 36.81% and 1 year total shareholder return of 37.55% suggest momentum has been...
OTCPK:NLST
OTCPK:NLSTElectronic

How Investors May Respond To Netlist (NLST) Swinging From Quarterly Loss To Profit On Surging Sales

In the first quarter ended March 28, 2026, Netlist, Inc. reported sales of US$104.89 million, up from US$28.98 million a year earlier, and turned a prior net loss of US$9.49 million into net income of US$8.65 million. This shift from loss to profit, alongside higher basic and diluted earnings per share of US$0.03 from continuing operations, highlights a sharp improvement in Netlist’s operating performance over the past year. With this earnings turnaround as a backdrop, we’ll now examine how...